Work with the leaders in Synthetic Genomics and Bio-Engineering.
Our synthetic genomics and bio-engineering expertise has significantly advanced our proprietary yeasts, enzymes, and production processes. Our high throughput Bio-Informatics platform seeks, filters, and discovers the unique and optimal enzymes from plants and other sources to domesticate for our novel production yeast strains. As a result, we can develop custom production process technologies to support and efficiently scale drug product manufacturing to meet clinical patient supply requirements’ demands and move swiftly through clinical development.
Our partnership program aims to align with innovative companies to discover, patent, and advance the research of some of the world’s most exciting compounds:
- Focusing on a partnership model to develop psychedelic, cannabinoid, or food tech compounds.
- Creating value and intellectual property protection for psychedelic, cannabinoid, and food tech programs.
- Providing pathways for partners to enter FDA Phase 1 and 2 clinical studies in 2022 with psychedelics.
Keep reading for more on our current scientific partners, along with additional information about how we can help your company through a partnership with CB Therapeutics.
